Ebidetide Injection (JY09) / 益百得肽注射液

1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of gastrointestinal adverse reactions is only 3–17%, significantly lower than that of Tirzepatide and Semaglutide.4. 1.     Offers clear benefits in weight reduction, islet function protection, microcirculation improvement, and cardiovascular/cerebrovascular protection.5.Phase III trials completed in over 1,100 patients with no serious adverse events, providing robust safety and efficacy data.6.Enables significantly lower production costs, offering a more accessible option for long-term treatment, especially suitable for low- and middle-income countries.